This is a preprint.
The Relationship of Cerebrospinal Fluid Biomarkers and Cognitive Performance in Frontotemporal Dementia
- PMID: 38410483
- PMCID: PMC10896374
- DOI: 10.21203/rs.3.rs-3945509/v2
The Relationship of Cerebrospinal Fluid Biomarkers and Cognitive Performance in Frontotemporal Dementia
Abstract
Objective: Currently available literature on the relationships between cerebrospinal fluid (CSF) biomarkers and cognitive performance in frontotemporal dementia (FTD) is very limited and inconclusive. In this study, we investigated the association of cognition, as measured with Montreal Cognitive Assessment (MoCA), with CSF levels of total tau (t-tau), phosphorylated tau at threonine 181 (p-tau181), and amyloid β 1-42 (Aβ1-42) in a group of patients with FTD and Alzheimer's disease (AD).
Methods: We conducted a retrospective cohort study with participants selected from the electronic records of patients seen at Yale New Haven Hospital's Memory Clinic, CT, USA. We included 61 patients, 28 with FTD (mean age=64.1) and 33 with AD (mean age=66.8).
Results: T-tau levels negatively and significantly correlated with total MoCA scores as well as the different MoCA index scores in both the FTD (r=-0.469, p<0.05) and AD (r=-0.545, p<0.01) groups. There were no significant associations with MoCA scores and p-tau181 levels in patients with FTD (r=-0.224, p>0.05), unlike patients with AD, who exhibited significant correlations (r=-0.549, p<0.01). Also, Aβ1-42 levels were not significantly correlated with MoCA scores in either of the FTD and AD groups.
Conclusion: CSF concentrations of t-tau are inversely correlated to cognitive performance in patients with FTD and both t-tau and p-tau181 in AD. These findings provide valuable insights into the relationship between clinical cognitive performance and tau-related pathology in FTD.
Keywords: Alzheimer’s Disease; CSF; Cognitive decline; Frontotemporal dementia.
Conflict of interest statement
Conflict of interest: All authors declare that they have no conflicts of interests.
Figures
Similar articles
-
Cerebrospinal Fluid Biomarkers and Cognition in Alzheimer Disease and Frontotemporal Dementia in a Memory Clinic Setting.Alzheimer Dis Assoc Disord. 2025 Jan-Mar 01;39(1):22-27. doi: 10.1097/WAD.0000000000000656. Epub 2025 Jan 13. Alzheimer Dis Assoc Disord. 2025. PMID: 40397510
-
Cerebrospinal fluid neurofilament light chain and total-tau as biomarkers of neurodegeneration in Alzheimer's disease and frontotemporal dementia.Neurobiol Dis. 2023 Oct 1;186:106267. doi: 10.1016/j.nbd.2023.106267. Epub 2023 Aug 29. Neurobiol Dis. 2023. PMID: 37652185
-
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.Alzheimers Res Ther. 2021 Mar 25;13(1):65. doi: 10.1186/s13195-021-00805-8. Alzheimers Res Ther. 2021. PMID: 33766131 Free PMC article.
-
Clinical indications for analysis of Alzheimer's disease CSF biomarkers.Rev Neurol (Paris). 2013 Oct;169(10):709-14. doi: 10.1016/j.neurol.2013.07.024. Epub 2013 Sep 6. Rev Neurol (Paris). 2013. PMID: 24016466 Review.
-
Executive Summary of 2023 International Conference of the Korean Dementia Association (IC-KDA 2023): A Report From the Academic Committee of the Korean Dementia Association.Dement Neurocogn Disord. 2024 Apr;23(2):75-88. doi: 10.12779/dnd.2024.23.2.75. Epub 2024 Apr 24. Dement Neurocogn Disord. 2024. PMID: 38720824 Free PMC article. Review.
References
-
- Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–77. Epub 20110802. doi: 10.1093/brain/awr179. - DOI - PMC - PubMed
-
- Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006–14. Epub 20110216. doi: 10.1212/WNL.0b013e31821103e6. - DOI - PMC - PubMed
-
- Strong MJ, Grace GM, Freedman M, Lomen-Hoerth C, Woolley S, Goldstein LH, Murphy J, Shoesmith C, Rosenfeld J, Leigh PN, Bruijn L, Ince P, Figlewicz D. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10(3):131–46. doi: 10.1080/17482960802654364. - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases